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| INTRODUCTION
Exacerbations are a major source of morbidity and economic burden in asthma 1 and can lead to poorer quality of life, 2 accelerated lung function decline, 2, 3 and premature mortality. 4 According to the Global Initiative for Asthma (GINA), 5 assessment of future risk of exacerbations is an important component of overall asthma management.
Existing clinical risk scores have been developed to predict shortterm (6-12 months) exacerbation risk, 6, 7 but given that asthma is a disease that can vary over time, these risk assessment scores may not be adequate for predicting long-term exacerbation risk. Knowledge of the long-term clinical trajectories of asthma, that is, patterns of occurrences of exacerbations over several years' duration, allows physicians to predict the future course of disease, stratify risk, and tailor treatment accordingly.
The aims of this study were to identify distinct clinical trajectories of severe exacerbation rates over five years among patients with problematic asthma, to identify baseline factors associated with different trajectories, and to develop and validate a clinical risk score to predict whether a patient will follow an unfavorable trajectory.
| MATERIALS AND METHODS

| Participants
This was a prospective, longitudinal, observational study conducted at the specialist asthma clinic at Singapore General Hospital, which receives referrals from primary care, inpatient discharges, and other respiratory physicians for difficult or severe asthma. We screened and recruited patients presenting in 2011 (derivation cohort) or 2012/ 2013 (validation cohort). All patients who were on step 4 of the GINA treatment ladder were identified and further screened to select subjects who fulfilled criteria for both "problematic asthma" and "uncontrolled asthma". "Problematic asthma" was defined according to the Innovative Medicines Initiative 8 which encompasses both difficult and severe asthma, the former referring to asthma that is uncontrolled despite high-intensity treatment due to poor compliance, psychosocial factors, environmental exposures, or comorbidities and the latter referring to patients with truly refractory disease requiring high-intensity treatment after exclusion of factors that may aggravate or complicate asthma. High-intensity treatment was defined as GINA treatment ladder ≥ step 4 (medium-or high-dose combination inhaled corticosteroids/long-acting beta agonists, ICS+LABA). 5 12 and an adjustment factor of 0.94 was applied for 
| Identification of clinically distinct trajectories and comparisons between trajectories
A trajectory describes the change of a measured variable over time.
To identify clinically distinct trajectories of severe exacerbation rates, we used the statistical method group-based trajectory modeling, 
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The Stata procedure Proc Traj was employed for this analysis. 15 The number of severe exacerbations was modeled as a zero-inflated
Poisson distribution or alternatively as a negative binomial distribution. Different models with varying number of groups and polynomial orders were compared to find the best-fit model. The number of trajectories specified in the model was increased stepwise from 2 to 5, and the best-fitting number of trajectories was selected using
Bayesian information criterion (BIC). After identifying the number of trajectories, different shapes for trajectories (intercept-only, linear,
quadratic, cubic) were tested. Patients were classified according to a specific trajectory on the basis of the maximum estimated probability of assignment. A probability of 0.9 or higher was considered an excellent fit, whereas a value of less than 0.7 was considered a poor fit. 15 
| Derivation of the clinical risk score
To derive the clinical risk score, we used a univariate-based method. 16 Baseline variables found to be significantly different in the most unfavorable trajectory compared to the other trajectories were selected for inclusion in the clinical risk score. Each variable was converted into a categorical variable, using cutoffs that were determined based on mean or median values of the different trajectory groups.
Each component of the risk score was then allocated a weight by first entering all the components into a multivariate logistic regression model predicting the probability of following the most unfavorable trajectory and then rounding up the regression coefficients to the nearest integers. The predictive accuracy of the final clinical risk score was expressed as area under the receiver operating characteristic curve.
| Validation of the trajectories and clinical risk score
External validation of the derived trajectories and clinical risk score was performed on an independent cohort presenting in 2012 and 2013, using severe exacerbation data spanning three years.
| Statistical analyses
The Student's t-test, Chi-square test, or Mann-Whitney test were used for parametric, categorical, or nonparametric data, respectively.
To test for monotonic trends, we used one-way ANOVA, linearby-linear analysis, or the Jonckheere-Terpstra test for parametric, categorical, or nonparametric variables, respectively.
| RESULTS
Of the 205 patients presenting in 2011 who were on GINA step 4 treatment, 177 met eligibility criteria and formed the derivation cohort. Baseline characteristics are shown in Table 1 
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Sensitivity and specificity of the risk score at different cut-points are shown in Table 4 . A cut-point of ≥3 had a sensitivity of 72.2%
and specificity of 81.1% for identifying persistently frequent severe exacerbators in the derivation cohort. The area under the receiver operating characteristics curve (AUC) ( Figure 3A ) was 0.84 (95% CI:
0.75-0.93, P<.001) indicating good accuracy at discriminating persistently frequent severe exacerbators.
In the validation cohort (Table 1 for baseline characteristics), group-based trajectory modeling replicated the three trajectories ( Figure 1B Figure 3B ) with an AUC of 0.94 (95% CI:
0.86-0.97) and good sensitivity/specificity at cut-points of ≥3 or ≥4 (Table 4) .
| DISCUSSION
In this five-year observational study, we have identified distinct clinical trajectories of problematic asthma: 1) stable disease with few, infrequent severe exacerbations, 2) frequent severe exacerbations initially, with resolution of recurrent exacerbations over time, or 3)
persistently frequent severe exacerbations with increased incidence of near-fatal asthma. We have also developed and prospectively validated a simple clinical risk prediction score capable of identifying, at baseline, patients who will subsequently follow the most unfavorable trajectory of persistently frequent severe exacerbations. The components of the clinical risk score are easy to use in clinical practice and had excellent performance in an independent validation cohort. The components are: ≥2 severe exacerbations in the past year (+2), history of NFA, BMI≥25kg/m 2 , GERD, depression, and OSA (+1 each).
A score of ≥3 represents high risk of an unfavorable trajectory.
By analyzing long-term trajectories, we have addressed a major unmet need in severe/difficult asthma of discerning prognosis and future risk of severe exacerbation occurrences over the long term.
Previous studies aimed at identifying distinct asthma phenotypes, for example, by cluster analysis, 18, 19 did not take into account long-term disease trajectory as a potential source of heterogeneity in asthma and used cross-sectional or short-term prospective data, thus limiting the usefulness of the derived phenotypes at discriminating future prognosis. Cluster analysis of the British Thoracic Society Severe Asthma Registry 20 found that cluster membership was not stable over a median follow-up of three years, indicating loss of validity over time, which in retrospect is not unexpected given our current data. Another study found that asthma clusters 21 could not predict future risk of exacerbations, the primary focus of our work. Existing scoring systems are only able to predict healthcare utilization in severe or difficult asthma over the short term (6-12 months), 6, 7 whereas the clinical risk score presented here identifies persistently frequent severe exacerbators over a prolonged period of up to 4 years. The components of the score are based on information readily available in the clinical setting and already have established associations with severe and difficult asthma. [22] [23] [24] [25] We propose that assessing future risk of severe exacerbations Indeed, the majority of problematic asthma patients presenting to specialist centers are uncontrolled due to reversible factors such as nonadherence, 27, 28 10 We focused exclusively on severe exacerbations (requiring hospitalization or ED visit) because these are associated with high healthcare burden, 1 are the most important objective and recognized markers of asthma control in both clinical and research settings, 10 and can be reliably assessed by our methodology. Second, the trajectories and clinical risk score were derived from an Asian cohort and degree of generalizability to other global populations requires future assessment. Additional validation in other populations and healthcare settings is warranted and a promising avenue for future work. Third, adherence in our cohort was suboptimal, potentially influencing recorded severe exacerbation rates. However, no significant differences in adherence rates could explain the distinct trajectories in our data. Furthermore, poor adherence is a well-recognized, real-world phenomenon occurring even in specialist asthma services. 27, 29 Despite our inclusion of current smokers in the initial analysis, trajectories were similar following repeat analysis excluding this group. While we assessed some limited data on serum eosinophils, our study did not assess other potential asthma biomarkers; however, future research should focus on investigating biomarkers with the potential to predict future trajectories.
Last but not least, this was a real-life study which is subject to a number of potential confounders, but nevertheless provides useful information on real-world patterns of disease.
In summary, patients with problematic asthma follow distinct ill- 
